Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908338 | 0.80 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTNPC1HTT | |
| SCHEMBL2909113 | 0.80 | ALDH1A1 (0.35) | ALDH1A1KDM4EMAPTNPC1NPSR1 | |
| SCHEMBL2902352 | 0.79 | ALDH1A1 (0.45) | ALDH1A1KDM4EMAPTNPC1PKM | |
| SCHEMBL2904995 | 0.79 | ALDH1A1 (0.38) | ALDH1A1KDM4EMAPTNPC1NPSR1 | |
| SCHEMBL2902342 | 0.79 | ALDH1A1 (0.54) | ALDH1A1KDM4EMAPTNPC1PKM | |
| SCHEMBL2904799 | 0.78 | KDM4E (0.37) | ALDH1A1KDM4EMAPTNPC1NPSR1 | |
| SCHEMBL2901686 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL2904628 | 0.78 | KDM4E (0.51) | ALDH1A1KDM4EMAPTNPC1HTT | |
| SCHEMBL2908482 | 0.77 | ALDH1A1 (0.41) | ALDH1A1KDM4EMAPTNPC1PKM | |
| SCHEMBL2907045 | 0.76 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPTNPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611107-B1 | 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2010-08-18 | — | — | EP | claimed |
| US-7566709-B2 | 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| EP-1611107-A1 | 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS | MERCK PATENT GmbH (DE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089910-A1 | 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | HTR1A, HTR1D, HTR5A | ALDH1A1 1336/4885KDM4E 3489/4885MAPT 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.